the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
June 6, 2011 – Today, we learn from Health Canada the following very important safety information: Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform you of important new safety information regarding fatal infusion related reactions following …
May 31, 2011 – The American Food and Drug Administration (FDA) has released today the following announcement aimed at physicians, family practices, and patients: ISSUE: FDA is aware of two newly published studies that evaluated the risk of venous thromboembolism …
April 23, 2011 – In the history of flawed and/or market-withdrawn drugs, Lumiracoxib [Joicela], formely known as [Prexige], may only be a footnote, hardly comparable to the attention received by the high flying but ill-fated Rofecoxib [Vioxx], Troglitazone [Rezulin], and …
April 15, 2011 – From a press release as of today, we learn the following (text unchanged from EMEA press release): The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that rare atypical fractures of …
April 15, 2011 – The American Food and Drug Adeministration (FDA) informed today that it continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL) primarily in adolescents and young adults …
January 14, 2011 – The American Food and Drug Administration (FDA) notified today healthcare professionals and patients about cases of rare, but severe liver injury, including two cases of acute liver failure leading to liver transplant in patients treated with …
Heart Medication Dronedarone [Multaq]: Risk of Severe Liver Injury Read more »
December 13, 2010 – We learn today that the European Medicines Agency (EMEA) has been informed of Pfizer’s decision to voluntarily withdraw Sitaxentan [Thelin] from the market worldwide further to new information on two cases of fatal liver injury. Pfizer …
September 24, 2010 – Please find below a very significant announcement by the European Medicines Agency (EMEA) regarding the market suspensions of Avandia throughout the European Union. 09/23/2010 – The European Medicines Agency today recommended the suspension of the marketing …
September 23, 2010 – We present here a very significant announcement by the American Food and Drug Administration (FDA) in its original. Please note that the European Medicines Agency (EMEA) also today recommended the suspension of the marketing authorisations for …
FDA Significantly Restricts Access to the Diabetes Drug Rosiglitazone [Avandia] Read more »
2010-08-15 – From a recent health safety alert we learn that FDA notified healthcare professionals and patients that Lamotrigine [Lamictal], a medication commonly used for seizures in children two years and older, and bipolar disorder in adults, can cause aseptic …
Lamotrigine [Lamictal]: DrugLabel Change Because Risk of Aseptic Meningitis Read more »